Cramer's Top Homebu...
Health Care: Drugs
Transition Therapeutics Inc. (TTHI: NASDAQ)
$3.06 0.00 | 0.00%
05/24/13 - 09:30 AM ET
Company Cash Flow
| Jun 2012 | Jun 2011 | Jun 2010 | Jun 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -12.07M | 13.32M | -18.32M | -19.27M |
| Operating Gains/Losses | -285.69K | 97.79K | -65.04K | 463.92K |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 234.64K | -198.54K | 1.46M | -365.29K |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 229.79K | -300.57K | -1.35M | -38.85K |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Working Capital | 0.00 | -881.69K | 0.00 | 0.00 |
| Other Non-Cash Items | 1.11M | -18.86M | -1.25M | 705.34K |
| Net Cash From Continuing Operations | -8.55M | -4.85M | -16.70M | -15.66M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -8.55M | -4.85M | -16.70M | -15.66M |
| Sale of Property, Plant & Equipment | 0.00 | 43.35K | 23.41K | 50.02K |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 69.18M | 88.33M | 247.37M |
| Purchases of Property, Plant & Equipment | -6.69K | -20.27K | -1.02M | -1.09M |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | -8.45M | -63.20M | -68.41M | -239.77M |
| Other Cash from Investing Activities | 7.45M | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -1.01M | 6.00M | 18.93M | 7.76M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 4.76M | 0.00 | 15.20K | 108.14K |
| Repayment of Long-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 4.76M | 0.00 | 15.20K | 108.14K |
| Effect of Exchange Rate Changes | 409.41K | -266.46K | -260.53K | 498.48K |
| Net Change in Cash & Cash Equivalents | -4.40M | 880.03K | 1.98M | -7.30M |
Portfolios with TTHI
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks With Big Insider Buy...
- UserThe 1000 Club
- UserBiotech for Obama Presidency
- ContributorStockerblog.com Canadian Li...
- UserPhels
Latest TTHI Headlines from TheStreet
- 5 Stocks Under $5 Making Big Moves 09.20.12 | 02:09 pm
- 7 Stocks Under $10 With Relative Strength 07.06.12 | 02:07 pm
- 5 Stocks With Huge Insider Buying 12.01.11 | 06:12 am
- Transition Therapeutics Inc. Stock Downgraded (TTHI) 05.23.11 | 08:05 am
- Transition Stock Gaps Up On Today's Open (TTHI) 03.21.11 | 09:03 am
- Transition Therapeutics Inc.: News Release 02.22.11 | 11:02 am
- Transition Stock Soars Higher (TTHI) 02.22.11 | 10:02 am
- Transition Therapeutics Inc. Stock Upgraded By TheStreet Ratings (TTHI) 02.09.11 | 05:02 pm
- Transition Therapeutics Announces Second Quarter Fiscal 2011 Financial Results 02.07.11 | 04:02 pm
- Transition Therapeutics To Hold Conference Call On Second Quarter Fiscal 2011 Financial Results On Monday, February 7th, At 4:30 P.M. EST 02.04.11 | 01:02 pm
Press Releases for TTHI
- Transition Therapeutics To Hold Conference Call On Third Quarter Fiscal 2013 Financial Results On Tuesday, May 7th, At 4:30 P.M. EST - PR Newswire 05.06.13 | 12:05 pm
- Transition Therapeutics Announces Results Of Clinical Study Of Type 2 Diabetes Drug Candidate TT-401 - PR Newswire 04.30.13 | 06:04 am
- Transition Therapeutics To Hold Conference Call On Second Quarter Fiscal 2013 Financial Results On Thursday, February 7th, At 4:30 P.M. EST - PR Newswire 02.04.13 | 12:02 pm
- Transition Therapeutics Announces Enrollment Of The First Patient In Phase 2 Study Of ELND005 (Scyllo-inositol) For The Treatment Of Agitation/Aggression In Patients With Alzheimer's Disease - PR Newswire 11.28.12 | 08:11 am
- Transition Therapeutics To Hold Conference Call On First Quarter Fiscal 2013 Financial Results On Thursday, November 8th, At 4:30 P.M. EST - PR Newswire 11.05.12 | 04:11 pm
- Transition Therapeutics To Hold Conference Call On Full Year Fiscal 2012 Financial Results On Thursday, September 13th, At 4:30 P.M. EST - PR Newswire 09.11.12 | 04:09 pm
- Transition Therapeutics Announces Dosing Of First Patient In Phase 2 Clinical Study Of ELND005 In Bipolar Disorder - PR Newswire 08.30.12 | 07:08 am
- Transition Therapeutics To Present At The Canaccord Genuity Annual Growth Conference - PR Newswire 08.13.12 | 04:08 pm
- LifeSci Advisors Announces Investment Opinion On Transition Therapeutics, Inc. - Business Wire 06.16.11 | 09:06 am
- Elan And Transition Therapeutics Announce Topline Summary Results Of Phase 2 Study And Plans For Phase 3 For ELND005 (Scyllo-inositol ) - Business Wire 08.09.10 | 04:08 pm
Partner Headlines for TTHI
- Transition Therapeutics To Trade Higher Into Upcoming Trial Results For Diabetes Drug - Seeking Alpha 01.28.13 | 09:01 am
- Elan Starts Phase II ELND005 Study - Analyst Blog - NASDAQ 09.06.12 | 08:09 pm
- Transition Therapeutics Announces ELND005 Phase 2 Clinical Trial Data to be Presented at the International Conference of Alzheimer's Disease (ICAD) Meeting - Benzinga 07.15.11 | 04:07 pm
- Morning Market Losers - Benzinga 05.31.11 | 10:05 am
- Morning Market Movers (FONR, TTHI, GFN, CEBK) - Benzinga 02.22.11 | 09:02 am
- Life Sciences Companies Raise Record Amounts of Capital - Seeking Alpha 12.31.10 | 04:12 pm
- Elan to Move ELND005 to Phase III - Analyst Blog - Zacks 08.16.10 | 04:08 pm
